These results demonstrated that PABPC3 expression levels influence the drug sensitivity and progression-free survival in ovarian cancer, suggesting PABPC3 as a potential therapeutic target or prognostic marker, offering new insights into the clinical management of ovarian cancer. This evidence concerns the gene PABPC3 and ovarian carcinoma.